Navigation Links
Post-Op Chemo Fails to Boost Survival in Stomach Cancers
Date:3/11/2008

Drug-surgery combo showed no significant improvement in outcomes, study finds

TUESDAY, March 11 (HealthDay News) -- Chemotherapy following surgery does not improve survival in stomach cancer patients, says an Italian study.

Currently, surgery is the only treatment that can potentially cure non-metastatic gastric cancer, according to background information in the study. However, some recent research has suggested that a chemotherapy combination of cisplatin, epirubicin, 5-fluorouracil and leucovorin (PELF) improves outcomes in people with metastatic gastric cancer.

In this study, researchers tested the PELF combination in patients with localized gastric cancer. Some of the 258 patients in the study were treated with surgery only, while others had surgery followed by chemotherapy.

At a median follow-up of 72.8 months, there was no statistical difference between the two groups in terms of disease-free survival or overall survival. Disease progression occurred in 47.7 percent of patients in the surgery/chemotherapy group and in 51.6 percent of those in the surgery group.

The survival rate was 47 percent in the surgery/chemotherapy group and 45.3 percent in the surgery group.

The study was published in the March 11 online issue of the Journal of the National Cancer Institute.

"Our study confirms that a dose-intense regimen like PELF, which showed very promising results in advanced gastric cancer, is not effective in an adjuvant setting," wrote the researchers from the University Hospital Careggi in Florence and the Italian Oncology Group for Cancer Research. Based on these and other recent negative findings, the authors concluded: "Adjuvant chemotherapy alone remains a controversial approach in operable gastric cancer."

In an accompanying editorial, two doctors at the Beijing Cancer Hospital and Institute in China discuss conflicting findings from recent trials examining the use of chemotherapy and radiation to treat patients with localized gastric cancer.

Even though overall data is inconsistent, chemotherapy, radiation or a combination of the two should be used in patients with localized gastric cancer, said Dr. Aiwen Wu and Dr. Jiafu Ji.

"Surgery alone is no longer the standard treatment for patients with resectable gastric cancer, independent of the patient population or the practice location," they wrote.

More information

The American Cancer Society has more about stomach cancer.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, March 11, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene Tied to Post-Op Delirium in Elderly
2. UI nursing researcher to study post-operative pain control
3. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
4. Acupuncture Cuts Need for Post-Op Painkillers
5. Chewing gum -- the new post-operative medicine
6. Chemotherapy may be culprit for fatigue in breast cancer survivors
7. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
8. To evade chemotherapy, some cancer cells mimic stem cells
9. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Post-Op Chemo Fails to Boost Survival in Stomach Cancers
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover ... O2X , an active lifestyle company that provides Human Performance Training and ... firefighters, police offers, first responders, military officers and others in service through the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... held the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 ... local medical community, offering physicians and healthcare providers an opportunity to learn about ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
(Date:4/21/2017)... ... , ... National pest management association survey conducted in 2010 and more recently ... the 5-year period. In 2015 10% or US$750 million per annum of the total ... , The health and economic consequences of bed bug infestations are only ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: